TP53 in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDSs) are heterogeneous for their morphology, clinical characteristics, survival of patients, and evolution to acute myeloid leukemia. Different prognostic scoring systems including the International Prognostic Scoring System (IPSS), the Revised IPSS, the WHO Typed Prognos...
Enregistré dans:
Auteurs principaux: | Yan Jiang, Su-Jun Gao, Benoit Soubise, Nathalie Douet-Guilbert, Zi-Ling Liu, Marie-Bérengère Troadec |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/ec8b25c4a03740d0ac190ec97f3a4263 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
<i>TP53</i> Combined Phenotype Score Is Associated with the Clinical Outcome of <i>TP53</i>-Mutated Myelodysplastic Syndromes
par: Mariko Yabe, et autres
Publié: (2021) -
Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
par: Edit Porpaczy, et autres
Publié: (2021) -
<i>APC</i> and <i>TP53</i> Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
par: Ramya Thota, et autres
Publié: (2021) -
<i>TP53</i> Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy
par: Humaira Noor, et autres
Publié: (2021) -
Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
par: Palacios-Campos,Adriana, et autres
Publié: (2020)